Ombitasvir–paritaprevir–ritonavir with or without dasabuvir is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults, as specified in table 1, only if the company provides ombitasvir–paritaprevir–ritonavir and dasabuvir at the same price or lower than that agreed with the Commercial Medicines Unit.
| HCV genotype, liver disease stage | Treatment | Duration (weeks) | Recommendation according to treatment history |
|---|---|---|---|
|
1a, without cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin |
12 |
Recommended |
|
1a, with compensated cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin |
24 |
Recommended |
|
1b, without cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir |
12 |
Recommended |
|
1b, with compensated cirrhosis |
Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin |
12 |
Recommended |
|
4, without cirrhosis |
Ombitasvir–paritaprevir–ritonavir with ribavirin |
12 |
Recommended |
|
4, with compensated cirrhosis |
Ombitasvir–paritaprevir–ritonavir with ribavirin |
24 |
Recommended |
Abbreviation: HCV, hepatitis C virus.
Note: Treated – the person's hepatitis C has not adequately responded to interferon‑based treatment.
It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.